XBiotech Inc. — Q2 2016 Form 10-Q
Reporting period: Three and six months ended June 30, 2016. Unaudited consolidated financial statements; amounts below are in U.S. dollars unless noted. XBiotech is a clinical-stage biopharmaceutical company developing True Human monoclonal antibodies, including lead candidate Xilonix for advanced colorectal cancer.
Financial results and liquidity
| Metric | Q2 2016 | Q2 2015 | Six months 2016 | Six months 2015 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $11.2m | $4.4m | $19.0m | $11.2m |
| General and administrative expense | $2.4m | $2.0m | $4.8m | $3.5m |
| Net loss | $13.6m | $6.7m | $23.9m | $14.9m |
| Loss per share, basic and diluted | $0.42 | $0.22 | $0.74 | $0.50 |
- Cash and cash equivalents were $64.8m at June 30, 2016, down from $91.1m at December 31, 2015. Current assets were $66.3m and current liabilities $10.4m.
- Six-month operating cash use was $18.2m, investing cash use $8.8m, and financing cash provided $0.7m. Cash declined by $26.3m over the period.
- Total liabilities were $10.4m; the balance sheet reports no borrowings or other debt. Shareholders’ equity was $82.8m. Accumulated deficit was $154.5m.
- Profitability and operating margins are not meaningful because the company had no revenue and incurred operating losses. No gross margin was reported.
Material changes and operating developments
- Q2 R&D expense rose 156% year over year; six-month R&D expense rose 70%. Management attributed the increase mainly to expanded clinical-trial activity, including global Xilonix studies, and higher laboratory, manufacturing-supply, and personnel costs.
- Six-month G&A expense increased 40%, reflecting workforce growth, stock compensation, professional fees, public-relations costs, insurance, travel, and recruiting.
- Construction in progress for the Austin manufacturing facility increased to $17.1m from $10.4m at year-end. The filing says completion, previously expected in August, was revised to the end of September 2016; estimated future payments to the general contractor were $8.9m, expected principally in Q3. The company also forecast $2.2m of additional construction spending and $6.7m for equipment.
- Cash used in investing activities increased from $2.2m to $8.8m year over year, primarily reflecting property, equipment, and facility spending. Unlike the first half of 2015, which included substantial IPO proceeds, first-half 2016 financing cash was limited to stock-option exercises.
Outlook, risks, and contingencies
- Management expected significant and increasing operating losses as it advanced candidates through development and sought regulatory approval and commercialization; it said profitability may never be achieved. The filing provides no specific revenue, earnings, or cash-burn guidance.
- XBiotech said its European marketing-authorization application for Xilonix remained on schedule for a possible 2016 decision by the EMA’s CHMP. It presented pivotal-trial data at the ESMO World Congress. Facility validation was expected to begin after construction completion.
- The filing identifies the need for future collaboration or product-sale receipts and/or financing to fund planned clinical operations. It includes a forward-looking statement concerning the company’s belief that cash flows could meet needs for at least 12 to 24 months, but provides no detailed runway forecast.
- Two purported securities class actions allege misleading statements concerning the European Phase III Xilonix trial. Damages sought are unspecified; the company said it could not estimate the outcome or financial impact. No trial dates had been set.
- The company reported no material market risk from financial instruments, interest rates, commodities, or foreign currencies and no hedging activity. It reported no material changes to the risk factors in its 2015 Form 10-K.
- On August 11, 2016, CFO Scott Whitehurst announced retirement for health reasons, effective immediately. Management concluded disclosure controls were effective and reported no material quarter changes to internal control over financial reporting.
Important facts for investors to verify
- Current clinical, regulatory, and commercialization status of Xilonix, including the European review timetable and the evidence supporting approval prospects.
- Cash runway assumptions against ongoing clinical spending, the planned facility and equipment outlays, and the absence of material operating revenue.
- Updated facility completion, validation, and total cost estimates, including the timing and amount of remaining contractor and equipment payments.
- Developments, potential exposure, and disclosure implications of the two securities lawsuits concerning Xilonix trial statements.
- Management and finance leadership changes following the CFO’s departure, and any subsequent updates to forecasts or controls.